Novartis AG (NVS) Rating Reiterated by J P Morgan Chase & Co
NVS has been the subject of several other reports. BidaskClub cut Novartis AG from a hold rating to a sell rating in a research note on Friday, August 11th. Cowen and Company set a $90.00 target price on Novartis AG and gave the stock a hold rating in a research note on Wednesday, August 9th. Zacks Investment Research cut Novartis AG from a buy rating to a hold rating in a research note on Friday, October 6th. Barclays PLC raised Novartis AG from an underweight rating to an equal weight rating in a research note on Thursday, June 22nd. Finally, Leerink Swann reissued a market perform rating and set a $83.00 target price on shares of Novartis AG in a research note on Thursday, June 22nd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $84.13.
Novartis AG (NYSE NVS) opened at 86.13 on Tuesday. Novartis AG has a 52-week low of $66.93 and a 52-week high of $86.90. The company has a market cap of $201.79 billion, a P/E ratio of 31.45 and a beta of 0.73. The stock’s 50 day moving average price is $85.22 and its 200-day moving average price is $81.80.
Novartis AG (NYSE:NVS) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The business had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. During the same period in the previous year, the firm posted $1.23 earnings per share. The company’s revenue was down 1.8% on a year-over-year basis. On average, equities analysts predict that Novartis AG will post $4.75 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/14/novartis-ag-nvs-rating-reiterated-by-j-p-morgan-chase-co.html.
Several institutional investors have recently bought and sold shares of NVS. City Holding Co. lifted its holdings in shares of Novartis AG by 4.6% in the 2nd quarter. City Holding Co. now owns 1,217 shares of the company’s stock valued at $102,000 after purchasing an additional 54 shares during the last quarter. WFG Advisors LP lifted its holdings in shares of Novartis AG by 38.1% in the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock valued at $102,000 after purchasing an additional 337 shares during the last quarter. Archford Capital Strategies LLC lifted its holdings in shares of Novartis AG by 72.3% in the 1st quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock valued at $110,000 after purchasing an additional 621 shares during the last quarter. Kernodle & Katon Asset Management Group LLC lifted its holdings in shares of Novartis AG by 3.4% in the 1st quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after purchasing an additional 49 shares during the last quarter. Finally, Massey Quick & Co. LLC purchased a new stake in shares of Novartis AG in the 1st quarter valued at about $119,000. 10.92% of the stock is owned by institutional investors and hedge funds.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.